


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



INSILICO MEDICINE

**InSilico Medicine Cayman TopCo**

**英矽智能**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 3696)**

## **VOLUNTARY ANNOUNCEMENT**

### **INSILICO'S RENTOSERTIB INHALATION SOLUTION RECEIVES IND APPROVAL FROM CDE**

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**InSilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that InSilico Medicine’s Investigational New Drug (the “**IND**”) application for its self-developed inhaled solution of Rentosertib (ISM001-055) for the treatment of adult idiopathic pulmonary fibrosis (the “**IPF**”) has been approved by the Center for Drug Evaluation of NMPA (the “**CDE**”). It is the 13th program from the Group’s AI-driven pipeline to obtain IND approval for conducting clinical trials.

The IND approval supports a Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of Rentosertib inhalation solution. The study will primarily consist of two parts: (1) a randomized, double-blind, placebo-controlled trial in healthy participants involving single ascending dose (SAD) and multiple ascending dose (MAD) cohorts; and (2) a non-randomized, open-label evaluation in patients with IPF receiving multiple doses. Approximately 80 subjects are expected to be enrolled.

#### **About Rentosertib (ISM001-055)**

Rentosertib (ISM001-055) is a potentially first-in-class small-molecule TNIK inhibitor, discovered and developed with the support of InSilico’s proprietary generative AI platform, Pharma.AI. The Food and Drug Administration of the U.S. (FDA) granted Orphan Drug Designation (ODD) to Rentosertib for the treatment of IPF in February 2023. The CDE announced the inclusion of Rentosertib in the list of Breakthrough Therapy Designation (BTD) in May 2025.

## Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board  
**InSilico Medicine Cayman TopCo**  
**Mr. Aleksandrs Zavoronkovs, Ph.D.**  
*Chairman, Executive Director, CEO and CBO*

Hong Kong, April 29, 2026

*As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.*